Background Sub-anesthetic ketamine prompts rapid and robust antidepressant response in
60-70% of patients with treatment resistant depression (TRD), however the underlying …

Ketamine has rapid and sustained antidepressant effects in patients with treatment-resistant
depression (TRD). However, the underlying mechanisms of action are not well understood …

Background Ketamine is an NMDA receptor antagonist and glutamate modulator with rapid
antidepressant effects in patients with treatment resistant depression (TRD). To gain insights …

Background A single intravenous administration of ketamine (0.5 mg/kg) in patients with
Treatment Resistant Depression (TRD) induces dramatic improvement in depression …

Conclusions: These findings advance our understanding of the acute effects of ketamine
administration on neural activation, which may inform future investigations of its cognitive …

Backgrounds Evidence suggested the crucial roles of brain-derived neurotrophic factor
(BDNF) and glutamate system functioning in the antidepressant mechanisms of low-dose …

Major depressive disorder (MDD) is one of the leading causes of morbidity and all-cause
mortality (including suicide) worldwide, and, unfortunately, first-line monoaminergic …

Low-dose ketamine is an efficacious antidepressant for treatment-resistant unipolar and
bipolar depressed patients. Major Depression Disorder patients receiving a single infusion …

Background The NMDA receptor antagonist ketamine was found to act as a fast-acting
antidepressant. The effects of single treatment were reported to persist for days to weeks …

Ketamine is an effective antidepressant, but there is substantial variability in patient
response and the precise mechanism of action is unclear. Neuroimaging can provide …